Mannkind (MNKD) Revenue (2010 - 2026)
Mannkind (MNKD) posted quarterly Revenue of $90.2 million for Q1 2026, up 15.08% year-over-year from $78.4 million in Q1 2025, and down 19.46% quarter-over-quarter from $112.0 million in Q4 2025.
Mannkind (MNKD) Revenue (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has reported Revenue for 14 consecutive years, with $90.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue rose 15.08% year-over-year to $90.2 million; the TTM figure through Mar 2026 stood at $360.8 million (up 21.23% YoY), while the FY2025 annual figure was $349.0 million, up 22.23% from the prior year.
- Revenue slipped to $90.2 million in Q1 2026 per MNKD's latest filing, from $112.0 million in the prior quarter.
- Across five years, Revenue topped out at $112.0 million in Q4 2025 and bottomed at $12.0 million in Q1 2022.
- Historically, Revenue has averaged $60.2 million across 5 years, with a median of $66.3 million in 2024.
- Annual changes were most pronounced in 2022 — Revenue sank 31.22% — and 2023, when it surged 238.78%.
- Mannkind's Revenue stood at $36.1 million in 2022, then jumped by 62.16% to $58.5 million in 2023, then soared by 31.3% to $76.8 million in 2024, then soared by 45.82% to $112.0 million in 2025, then declined by 19.46% to $90.2 million in 2026.
- Business Quant data shows MNKD's Revenue at $90.2 million in Q1 2026, $112.0 million in Q4 2025, and $82.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Mannkind | 1.19 Bn | 1.08 Bn | 94.97 Mn | 109.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 109.37 Mn |
| Mar 31, 2026 | 90.17 Mn |
| Dec 31, 2025 | 111.96 Mn |
| Sep 30, 2025 | 82.13 Mn |
| Jun 30, 2025 | 76.53 Mn |
| Mar 31, 2025 | 78.35 Mn |
| Dec 31, 2024 | 76.78 Mn |
| Sep 30, 2024 | 70.08 Mn |
| Jun 30, 2024 | 72.39 Mn |
| Mar 31, 2024 | 66.26 Mn |
| Dec 31, 2023 | 58.47 Mn |
| Sep 30, 2023 | 51.25 Mn |
| Jun 30, 2023 | 48.61 Mn |
| Mar 31, 2023 | 40.63 Mn |
| Dec 31, 2022 | 36.06 Mn |
| Sep 30, 2022 | 32.83 Mn |
| Jun 30, 2022 | 18.89 Mn |
| Mar 31, 2022 | 11.99 Mn |
| Dec 31, 2021 | 12.52 Mn |
| Sep 30, 2021 | 22.21 Mn |